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Abstract
Objectives There are more than 7000 rare diseases in
the USA, and they are prevalent in 8% of the population.
Due to life-threatening risk and limited therapies, early
detection and treatment are critical. The purpose of this
study was to explore characteristics of visits for patients
with rare diseases seen by primary care physicians (PCPs).
Design The study used a cross sectional study using a
national representative dataset, the National Ambulatory
Medical Care Survey for the years 2012–2014.
Setting Primary care setting.
Participants Visits to PCPs (n=22 306 representing 354
507 772 office visits to PCPs).
Primary outcome measures Prevalence of rare diseases
in visits of PCPs was the primary outcome. Bivariate
analyses and logistic regression analyses were used to
compare patients with rare diseases and those without
rare diseases and examined characteristics of PCP visits
for rare diseases and practice pattern.
Results Among outpatient visits to PCPs, rare diseases
account for 1.6% of the visits. The majority of patients
with rare diseases were established patients (93.0%) and
almost half (49.0%) were enrolled in public insurance
programmes. The time spent in visits for rare diseases
(22.4 min) and visits for more common diseases (21.3 min)
was not significantly different (p=0.09). In an adjusted
model controlling for patient characteristics (age, sex,
types of insurance, reason for this visit, total number of
chronic disease, having a rare disease and established or
new patient), patients with rare diseases were 52% more
likely to be referred to another provider (OR 1.52, 95% CI,
1.01 to 2.28).
Conclusions Visits for rare diseases are uncommon in
primary care practice. Future research may help to explain
whether this low level of management of rare diseases in
primary care practice is consistent with a goal of a broad
scope of care.

Introduction
Primary care physicians (PCPs) are trained
to provide care for a broad scope of conditions within their patient population. When
PCPs maintain a broad scope of practice this
safeguards access and quality of care for the
general population. Some of these conditions are managed directly by the PCP and

Strengths and limitations of this study
►► This study is the first research to investigate char-

acteristics of patients with rare diseases seen in
primary care practice and the association between
physician referral and rare disease diagnosis.
►► The study used population-based national representative data allowing for generalisability.
►► Primary care physicians may play a vital role in providing continuous care and managing patients with
rare diseases effectively.
►► The study is limited to the actions recorded in one
visit due to study design.
►► The study was unable to determine if that referral
is for a consult or part of a shared care relationship
between primary care and specialty care.

with others the PCP coordinates the care for
the patient. One recent study indicated that
in 1 year, family physicians typically manage
about 1700 diagnoses in office visits, with 100
diagnoses managed frequently.1
In addition to common, high prevalence diseases like diabetes, hypertension
and arthritis, a substantial proportion of
the general patient population, has a rare
disease, or diseases. As of 2017, the National
Institute of Health Genetic and Rare Disease
(GARD) Information Center had identified
7000 rare diseases, affecting approximately
25–30 million people in the US population.2
Rare diseases are categorised as life-threatening, with only few limited effective therapies available. In addition to the emotional
and physical burden associated with diagnosis, patients with a rare disease often face
financial burden due to the significant cost
associated with drugs and therapies. As such,
early detection and treatment are critical.
For example, in one study, more than half
of patients with rare diseases being seen at a
PCP practice had been diagnosed with rare
diseases at a PCP practice.3
However, to date there have been few
studies investigating the role of PCPs in the
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management of patients with rare diseases. The purpose
of this study was to examine in a nationally representative sample of visits, the prevalence of rare diseases cared
for in primary care practice as well as characteristics of
patients and providers.

Methods
This study used the National Ambulatory Medical Care
Survey (NAMCS), a national representative dataset, for
the years of 2012 to 2014. The NAMCS is a national probability sample survey of ambulatory medical care visits
to office-based physicians that allows for national estimates regarding medical care in the USA.3 Non-federally
employed physicians defined by the American Medical
Association and the American Osteopathic Association
who were principally engaged in patient care activities
and who are not specialised in anaesthesiology, pathology
and radiology were eligible. Also physicians who are
younger than 85 years of age at the time of the survey
were eligible. Based on multistage probability design,
eligible PCPs were selected and informed about the survey
and those who agreed to participate to the survey were
included in the data.3 NAMCS data are collected annually by the National Center for Health Statistics (NCHS).
It is electronic record collected by the Census Bureau in
the USA and multiple steps were implemented to process
and review the data based on the NCHS protocol. The
data estimates to be reliable met two criteria, (1) sample
records should be at least 30, and (2) a relative SE should
be 30% or less.3 The sample frame for NAMCS data in the
years 2012–2014 was composed of PCPs who specialise in
primary care (eg, general and family practice, internal
medicine and paediatrics), and who identified themselves
as the PCP of the patient.4 This list conforms to the definition used by the NAMCS to categorise primary care.
Diagnosis was determined based upon the International
Classification of Diseases (ICD)-9 codes and the diagnosis
made by a PCP at a visit was electronically recorded in the
patient record form. The patient report form provided
pre-existing conditions, current diagnosis and new diagnosis.5 Thus, more than 30 diagnoses can be managed
via this report form.6 Furthermore, this report form
allows us to identify established patients who have visited
before whereas it does not allow us to estimate numbers
of previous visits. The unweighted sample size was 22 306
representing 354 507 772 office visits to PCPs in the USA
from 2012 to 2014.
Rare disease
A rare disease is defined as a disease or a disorder that
affects fewer than 200 000 people in the USA.2 7 For this
study, diagnoses were identified as a rare disease using
the list provided by the GARD Information Center.2 Two
independent researchers and (ie, Dr Jo and Larson) and
one family medicine physician (ie, Dr Carek) reviewed
all new diagnosis in designated study years and identified rare diseases by comparing the list of GARD. With
2

consensus agreements, rare diseases for the study were
determined.
Independent variables
Demographics of patients seen by PCPs, such as age,
gender and race/ethnicity, were used. Gender and race/
ethnicity (ie, non-Hispanic White, non-Hispanic Black,
Hispanics and Others) were considered categorical variables whereas age was used as a continuous variable. In
addition, their form of health insurance, major reason for
the visit and total number of diagnosed chronic diseases
were included as categorical variables. Health insurance
was stratified into four categories: private insurance,
public insurance such as Medicaid and Medicare, self-pay
and others. Major reason for the visit was also categorised into four groups: new problems, chronic problems,
presurgery or postsurgery care and preventive care.
Providers’ characteristics including practice location
(ie, urban or rural), referral to other providers (ie, yes or
no) were examined. Time spent with providers in primary
care setting was compared between patients with rare
diseases and those without rare diseases. Time spent with
providers in primary care is the length of the time the
provider spent with the patient at the office and patient’s
waiting time to see the provider, receive care from
providers and prepare for a patient such as reviewing
medical chart or physical examination were excluded.3
Statistical analysis
To account for the complex survey design used in the
NAMCS, a weighted variable was used to consider survey
design effect. This allows for us to provide national estimates of USA ambulatory healthcare visits to office-based
physicians and community health centres.3 Also, it allows
us to produce national estimates of the ambulatory healthcare use in the USA.3 The prevalence of rare disease seen
in the primary care office visit was estimated. Χ2 tests were
used to compare characteristics of PCPs who care for rare
diseases against those who do not. Logistic regression was
also employed to examine the association between PCP
referral to other providers and patient diagnosis of a rare
disease. All analyses were conducted in SAS V.9.4.
Patient and public involvement
Patients and/or public were not involved in this study.

Results
The final sample was 22 306 representing 354 507 772
office visits to PCPs in the USA from 2012 to 2014. A total of
1508 PCPs participated to submit data for sample patient
visits. Of the total patient visits to a PCP, a rare disease was
noted in 1.6% of those visits. PCPs cared for 177 different
rare diseases. Patients with rare diseases were significantly older than those without rare diseases (age difference=8.3 years, p<0.01), while no significant differences
were found in the distribution of sex and race/ethnicity
(table 1). The majority of patients with rare diseases
Jo A, et al. BMJ Open 2019;9:e027248. doi:10.1136/bmjopen-2018-027248
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Table 1 Characteristics of patients with rare diseases in
primary care, National Ambulatory Medical Care Survey
2012–2014 (unweighted n=22 306, weighted n=354 507 772)
Patients
with rare
diseases
(%)

Patients
without rare
diseases
(%)
P value

Table 2 Practice characteristics of primary care physicians
who care for patients with rare diseases using National
Ambulatory Medical Care Survey, 2012–2014
Patients
with rare
diseases

Patients
without rare
diseases
P value

Practising area
 Urban

84.5

86.4

 Rural

15.5

13.6

Unweighted sample size 363
Weighted sample size
5 581 791

21 943
348 925 981

Mean age (years)*

47.7

39.4

<0.001

Referral to other
providers*

56.4

53.8

0.44

 Yes

14.3

9.0

0.01

 Non-Hispanic White

75.0

70.6

0.54

85.7
22.4

91.0
21.3

0.09

 Non-Hispanic Black

8.6

10.1

 No
Time spent with
providers (min)

 Hispanics

11.7

14.3

 Others

4.7

5.0

 Private insurance

49.3

54.6

 Public insurance

47.3

40.0

 Self-pay

1.8

3.5

 Other

1.5

1.9

Sex
 Female
Race

*Statistical significant level at 0.05.

Insurance types
0.15

Major reasons for this visit*
 New problems

33.7

42.6

 Chronic problems

39.0

28.7

 Presurgery/
postsurgery

27.3

28.7

 Preventive care
Total number of chronic
diseases*

0.0
1.3

0.0
1.0

0.32

0.002

disease was also not associated with rurality (p=0.32)
(table 2).
In an unadjusted regression model, patients with
rare diseases were 69% more likely to be referred to
other providers than those without rare diseases. After
controlling for covariates, such as patients’ characteristics (ie, age, sex, race/ethnicity, types of insurance, major
reason for this visit, total number of chronic disease,
having a rare disease and established or new patient),
patients with rare diseases were 52% more likely to be
referred to another provider than those without rare
diseases (table 3).

0.001

*Statistical significant level at 0.05.

were established patients (93.0%), having been seen by
the PCP more than one time, and almost half (49.3%)
were enrolled in private insurance programmes. Of the
visits for patients diagnosed with a rare disease, 39.0%
visited their PCPs with a comorbid chronic problem. In
addition, they had a significantly higher total number
of chronic diseases compared with patients without rare
diseases (p<0.01) (table 1).
Of visits by patients with rare disease, 14.3% were
referred to other providers (table 2). While PCPs spent
slightly more time with their patients who had rare diseases
(22.4 min), compared with patients without rare diseases
(21.3 min), it was not significantly different (table 2). The
majority of visits for patients with rare diseases and more
common diseases who were seen by PCPs were located in
urban areas. PCPs practising in rural areas (7.6%) were
not significantly less likely than PCPs practising in urban
areas (16.8%; p=0.06) to refer patients with rare diseases
to another physician. In a bivariate analysis, care for rare
Jo A, et al. BMJ Open 2019;9:e027248. doi:10.1136/bmjopen-2018-027248

Discussion
This study found that few patients with a rare disease
were identified as being managed in primary care practice. Patients with rare diseases in the primary care setting
show significantly older and have more comorbidities
compared with those without a rare disease diagnosis
whereas patients with rare diseases are comparable to
those without rare diseases in terms of sex distribution, race/ethnicity and types of health insurance. Not
Table 3 ORs of referral using unadjusted and adjusted
logistic regression analyses using National Ambulatory
Medical Care Survey, 2012–2014
Unadjusted OR
(95% CI)
Not having a rare Reference
disease
Having a rare
1.69 (1.15 to 2.48)*
disease

Adjusted OR
(95% CI)
Reference
1.52 (1.01 to 2.28)*†

*Statistical significant level at 0.05.
†Controlled for age, gender, race/ethnicity, types of insurance,
major reason for this visit, total number of chronic disease, having
a rare disease and established versus new patient.
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surprisingly, visits in primary care for patients diagnosed
with rare diseases are more likely than patients without
rare diseases to lead to referral to another provider. To
our knowledge, this is the first study to investigate characteristics of patients with rare diseases seen in primary care
practice and the association between physician referral
and rare disease diagnosis.
Much of medical practice and the corresponding
comfort in diagnosing and treating conditions is affected
by the frequency of occurrence of the condition and
pattern recognition. Rare diseases are by their very
nature uncommon and thus PCPs may not always feel
comfortable with the nuances of treatment and potential
complications for a disease that they encounter very infrequently. According to the National Academy of Medicine,
since rare diseases tend to accompany multiple common
conditions, it disrupts a clinician’s ability to recognise
clues of rare diseases.8 In many of these cases PCPs need
more than a consult from a specialist, especially when the
primary care team does not have the specialised medical
knowledge. Receiving all of their care from specialists
may not be the best situation for the patient. Patients with
rare diseases need to be managed in primary care or at
least have shared care between primary care and specialists in complementary roles to provide a more effective
management of these complex patients.
There are some limitations to this study. First, due to
the design of the NAMCS we are limited to the actions
recorded in that one visit. The design does allow us to
have an understanding of the types of patients seen in
primary care but it is not data on a cohort of patients.
Thus, we do not know what sort of care may have transpired between the patient and the physician in previous
visits. Also, it is not able to explore the linkage of multiple
consultations with specialists previsit or postvisit to PCPs.
Second, we are able to see if patients are referred in that
one visit, we are unable to determine if that referral is for
a consult or part of a shared care relationship between
primary care and specialty care.

Conclusion
This study identified characteristics of patients with rare
diseases who are seen in primary care practice and the
delivery patterns of PCPs managing patients with rare

4

diseases. Findings from this study suggest that PCPs
must possess a broad scope of practice in order to deliver
comprehensive, high-quality care. A better understanding
of the overall management of patients with rare diseases
managed solely outside of primary care would help to
improve the care for these patients.
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